Weight Loss with Monjaro and Ozempic

Introduction to Weight Loss Medications

• The American College of Cardiology recommends tirzepatide as the preferred first-line choice for weight loss in adults with obesity, with a 20.9% weight loss compared to semaglutide's 14.9% at therapeutic doses 1, 2

Patient Eligibility Criteria

• Patients with a BMI ≥30 kg/m² without additional risk factors, or a BMI ≥27 kg/m² with at least one weight-related comorbidity, are eligible for these medications, according to the Gastroenterology society 3, 4, 5, 1

Medication Selection Algorithm

• The American Heart Association suggests prioritizing tirzepatide 15mg weekly when maximum weight loss is the primary goal, with a 20.9% weight loss at 72 weeks versus semaglutide's 14.9% 1, 2
• The Endocrine Society recommends semaglutide 2.4mg weekly if tirzepatide is unavailable, not tolerated, or if the patient has established cardiovascular disease, with a 20% reduction in cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.80) 1, 2

Expected Weight Loss Outcomes

• The Obesity Society reports that tirzepatide achieves 15-21% weight loss at higher doses over 72 weeks 1
• The American Diabetes Association states that semaglutide 2.4mg achieves 14.9-17.4% weight loss in non-diabetic patients with obesity over 68 weeks 2

Mandatory Lifestyle Modifications

• The Academy of Nutrition and Dietetics recommends combining pharmacotherapy with a caloric deficit of 500-kcal reduction below daily requirements, minimum 150 minutes/week of physical activity, and resistance training to preserve lean body mass 1

Safety Profile and Adverse Effects

• The American Gastroenterological Association notes that common gastrointestinal effects of these medications include nausea (17-44% of patients), diarrhea (12-32%), vomiting (7-25%), and constipation (10-23%) 1, 2
• The National Kidney Foundation warns of serious but rare risks, including pancreatitis, gallbladder disease, and acute kidney injury 1, 2

Cardiovascular Benefits Beyond Weight Loss

• The American College of Cardiology reports that semaglutide 2.4mg reduces cardiovascular events by 20% (HR 0.80) in patients with obesity and established cardiovascular disease 1, 2

Special Population Considerations

• The American Diabetes Association recommends that patients with type 2 diabetes be prioritized for tirzepatide or semaglutide 2.4mg due to greater HbA1c reduction 1, 2
• The American Heart Association suggests that patients with cardiovascular disease be prioritized for semaglutide 2.4mg due to proven cardiovascular benefit 1, 2